Table 3 Response evaluation criteria in solid tumors responses to conventional chemotherapy in patients with advanced solitary fibrous tumors (n = 25)*
From: The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis
Chemotherapy | Response to chemotherapy n (%) | |
|---|---|---|
| Â | Stable disease | Progressive disease |
First-line therapy (n = 18) | 16 (89%) | 2 (11%) |
  All doxorubicin-based therapies | 14 | 1 |
   Doxorubicin + ifosfamide | 11 | 1 |
   Doxorubicin + dacarbazine | 1 | 0 |
   Doxorubicin + cisplatin | 1 | 0 |
   Doxorubicin | 1 | 0 |
  All gemcitabine-based therapies | 1 | 1 |
   Gemcitabine + docetaxel | 0 | 1 |
   Gemcitabine | 1 | 0 |
  Paclitaxel | 1 | 0 |
Second-line therapy (n = 6) | 4 (67%) | 2 (33%) |
  Gemcitabine | 1 | 1 |
  Paclitaxel | 3 | 1 |
Third-line therapy (n = 1) | 0 (0%) | 1 (100%) |
  Gemcitabine | 0 | 1 |
All lines of therapy (n = 25) | 20 (80%) | 5 (20%) |